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Abstract.  Mastoparan is a cationic amphipathetic pep- 
tide that activates trimeric G proteins,  and increases 
binding of the coat protein ~-COP to Golgi mem- 
branes.  ARFp13 is a cationic amphipathic peptide that 
is a putative specific inhibitor of ARF function, and 
inhibits coat protein binding to Golgi membranes. 
Using a combination of high resolution, three- 
dimensional electron microscopy and cell-free Golgi 
transport assays, we show that both of these peptides 
inhibit in vitro Golgi transport,  not by interfering  in 
the normal functioning of GTP-binding proteins, but 
by damaging membranes.  Inhibition of transport is 
correlated with inhibition of nucleotide sugar uptake 
and protein glycoslation, a decrease in the fraction 
of Golgi cisternae exhibiting normal morphology, 
and a decrease in the density of Golgi-coated buds and 
vesicles. At peptide concentrations near the ICs0 for 
transport,  those cisternae with apparently normal mor- 
phology had a higher steady state level of coated buds 
and vesicles. Kinetic analysis suggests that this in- 
crease in density was due to a decrease in the rate of 
vesicle fission. Pertussis toxin treatment of the mem- 
branes appeared to increase the rate of vesicle forma- 
tion, but did not prevent the membrane damage in- 
duced by mastoparan.  We conclude that ARFpl3 is 
not a  specific inhibitor of ARF function, as originally 
proposed, and that surface active peptides,  such as 
mastoparan,  have the potential for introducing artifacts 
that complicate the analysis of trimeric G protein in- 
volvement in regulation of Golgi vesicle dynamics. 
T 
hE movement of secretory proteins through the Golgi 
complex may involve multiple vesicular transport steps. 
Genetic and biochemical studies have revealed that the 
trafficking of transport vesicles is regulated  by members of 
at  least three different  GTP-binding  protein families:  Rab 
proteins  (37),  ADP-ribosylation  factors (ARFs; t 35),  and 
trimeric G proteins,  (4, 7). The molecular details of these 
regulatory pathways,  however,  have been difficult  to elu- 
cidate. 
Peptides designed to interfere  with GTP-binding  protein 
activity have been widely used as probes for the function of 
GTP-binding  proteins  in  protein transport.  These include 
peptides corresponding to the putative effector  domain  of 
Rab proteins (16, 30, 39, 40), peptides that correspond to the 
NH2-terminal domain of ARF proteins (3, 24, 28, 34), and 
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peptides that mimic the trimeric G protein interacting  do- 
main of G protein-coupled receptors (9,  10, 13, 26, 29). A 
role for these various GTP-binding proteins in protein trans- 
port, as suggested by peptide studies, has in many cases been 
substantiated  by independent  approaches  (15, 48,  49,  54). 
Nevertheless,  the characteristics  of peptide action in in vitro 
transport  systems  are often different  than  those observed 
when  the  cognate  GTP-binding  protein  is  inactivated  by 
other means (15, 49) or removed (47).  Moreover,  competi- 
tion between peptides and their cognate GTP-binding  pro- 
teins has been difficult to demonstrate (24, 47), raising the 
possibility that some peptide reagents are not as specific as 
originally  thought  (31). 
We have used the in vitro Golgi transport system of Roth- 
man and colleagues  to investigate the mechanism  of action 
of two peptides reported to have opposing effects on coat pro- 
tein binding  to Golgi membranes.  Mastoparan (MAS; Fig. 
1 A), is a cationic  amphipathic  peptide that stimulates  tri- 
meric G protein GTP/GDP exchange by mimicking the inter- 
action domain of G protein-coupled receptors (21, 22). In 
semi-intact  cells, this peptide stimulates binding of the vesi- 
cle coat protein,  /3-COP, to Golgi membranes  (26).  The 
stimulatory effect of the peptide is largely abolished by per- 
tussis  toxin-catalyzed  ADP ribosylation  of G~i/o subunits. 
These findings  are consistent  with other evidence that tri- 
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Golgi complex (17, 33, 41, 45). ARFpl3 is an amphipathic 
peptide  corresponding  to  the  NH2-terminal  sequence  of 
ARF (Fig. 1 B), which is thought to be a critical determinant 
of ARF activities (24).  This peptide is a potent inhibitor of 
the ADP-ribosylating activity of ARF (24),  of transport in 
several in vitro systems (3, 24, 28), and of vesicle formation 
on Golgi membranes (24).  Although this peptide has been 
proposed to compete with ARF, competition has not been 
demonstrable (24,  47).  Given the structural similarity be- 
tween these NH2-terminal  sequences of ARF and MAS, it 
has been suggested that ARF may interact with a trimeric 
G protein to exert its effects (24).  The ability of MAS to 
stimulate and ARFpl3 to inhibit coat protein binding could 
thus represent activation of different trimeric G proteins that 
have opposing roles in the regulation of vesicular transport, 
as has been proposed for vesicle formation in the TGN (4). 
We demonstrate that both MAS and ARFpl3 are potent 
inhibitors of in vitro Golgi transport. Inhibition is specific 
for MAS  analogs  that stimulate nucleotide exchange on 
purified G protein subunits, and for ARF peptides that in- 
hibit the ADP-ribosylating activity of ARF. Nevertheless, 
inhibition is not due to activation of G proteins, but rather 
to a generalized effect on membrane function, including in- 
hibition of nucleotide sugar uptake and protein glycosyla- 
tion. Morphological analysis using high resolution, three- 
dimensional imaging reveals that these amphipathic peptides 
induce changes in cisternal architecture indicative of mem- 
brane damage. The significance of these findings and their 
implications are discussed. 
Materials and Methods 
Materials and Reagents 
Golgi-enriched membranes were prepared as previously described (1). Do- 
nor Golgi were prepared from N-acetylglucosamine  (GIcNAc) transferase 
I-deficient CHO Lec 1 cells (44) infected with vesicular stomatitis virus 
(VSV) in suspension culture (12). Acceptor Golgi were prepared from CHO 
pro-s cells (parental  line of CHO I.~ 1; 44). CHO cytosol was prepared 
from CHO Lec 1 cells as described by Block ct al. (5). Bovine brain cytosol 
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Figure 1. Helical wheel projections  of MAS and ARFpl3. (A) Heli- 
cal wheel projection of MAS. The active analog, MAST, has A and 
L at positions 12 and 13, respectively. The inactive analog, MAS17, 
has K and L at positions 6 and 13, respectively. (B) Helical wheel 
projection of the first 13 amino acids of ARFpl3, as described by 
Kahn et al. (24). The inactive analog, ARFp28, is lacking the first 
four amino acids of the sequence. 
fractions 1,2,3, and 4 were prepared according  to the procedure of Clary 
and Rothman (11). ARF-depleted  cytosol was prepared as described by Tay- 
lor and Melan~on (46).  UDP-[3HI-N-GIcNAc was synthesized from [31-t]- 
glucosamine (New England Nuclear,  Wilmington, DE) using the method 
of Lang and Kornfeid (27).  Protein concentrations were determined with 
bicinchoninic acid (43;  Pierce,  Rockford,  IL). MAS was purchased from 
Sigma Chemical Company (St. Louis, MO). MAS 7 and MAS 17 were kind 
gifts of Drs. M. Colombo and P. Stahl (Washington University, St. Louis, 
MO). ARFpl3 and ARFp28 were kind gifts of Drs. J. Donaldson and R. 
Klansner (National Institutes of Health, Bethesda,  MD). To facilitate direct 
comparisons,  the peptide concentrations were determined by ninhydrin as- 
say after alkaline hydrolysis (23) using leucine as standard. All of the pep- 
tide preparations were found to contain significant amounts of non-peptide 
solids  (50-80%). All reagents were of the highest grade available. 
Cell-free Golgi Transport  Assays 
Golgi transport assays were performed as previously described (1). A typi- 
cal 25 ~1 Golgi transport assay contained 2.5/~1 each of donor and acceptor 
membranes, 2.5 #1 of cytosol,  10 #M palmitoyl  coenzyme A, an ATP- 
regenerating  system (50/~M ATP, 5 mM creatine phosphate,  11.9 IU/ml 
creatine phosphokinase), 250/~M UTP, 0.I mM DTT, 0.2 M sucrose, 0.25 
/LCi UDP-[3H]-GIcNAc, and buffer salts (25 mM Hepes,  pH 7.0, 20 mM 
KCI, 2.5 mM magnesium acetate).  The concentrations of membrane and 
cytosolic protein are stated in the figure legends. Assays were incubated for 
60 min at 37°C, and VSV glycoprotein (VSV-g)  protein was immunoprecipi- 
tated and collected  on filters for scintillation  counting. 
Assays for Glycosylation, Nucleotide Sugar Uptake, 
and Membrane Integrity 
A two stage incubation was used to measure inhibition  of glycosylation after 
VSV-g protein had been transported to the acceptor compartment (20), In 
stage  I,  a  standard  Golgi  transport assay  mixture lacking  UDP-[3H]  - 
GIcNAc was incubated for 45 min at 37°C to allow VSV-g protein to ac- 
cumulate in the acceptor compartment. Inhibitors were then added, and the 
incubation continued for an additional  15 rain at 37°C. In stage II, the Golgi 
membranes were re-isolated by centrifugation,  and then incubated at 37°C 
in 25 #1 of glycosylation buffer (25 mM Hepes,  pH 7.0, 15 mM KCI, 2.5 
mM Mg acetate,  0.2 M sucrose,  ATP-regenerating system, 250 #M UTP, 
250 #g/ml nucleotide  monophosphate kinase,  and 0.25  #Ci UDP-[3H]  - 
GIcNAc; 20) for up to 80 min, followed by immunoprecipitation of VSV-g 
protein, as described above. 
Soluble assays for galactose (Gal) and GlcNAc transferase activities were 
performed as described by Dunphy and Rothman (18). Glycosylatiun  of 
VSV-g protein and nucleotide  sugar uptake  were  measured with VSV- 
infected Pro  -5 (wild type) membranes that were rendered incompetent for 
transport by inactivation of the NEM-sensitive factor (NSF)  (5, 35).  The 
membranes were incubated in a standard transport reaction mixture con- 
taining 0.25  #Ci of either UDP-[3H]-GIcNAc,  UDP-[3H]-Gal,  or CMP- 
[3H]-sialic acid plus 10 #M CTP,  with or without inhibitors. Nucleotide 
sugar uptake was measured after 15 min of incubation by removing dupli- 
cate 25/~1 samples, diluting them with 75 #1 of cold buffer (25 mM Hepes, 
pH 7.0, 15 mM KCI, 2.5 mM Mg acetate, 0.3 M sucrose),  and isolating the 
membranes by centrifugation in a microfuge  for 5 min. The pellets were 
washed twice with 100/~1  of cold buffer, and transferred to vials for scintilla- 
tion counting. Giycosylation of endogenous VSV-g protein was measured by 
immunoprecipitating VSV-g protein from duplicate  25 #1 samples  of the 
reaction mixture after a  1-h incubation (47). 
Membrane integrity  was  assessed  by  incubating VSV-infected pro-5 
membranes in a transport reaction for 5  min to accumulate UDP-[3H]  - 
GlcNAc in Golgi compartments,  thereby establishing a concentration gra- 
dient of UDP-[3H]-GIcNAc across the membrane (50).  The membranes 
were then incubated for an additional  10 rain with inhibitors to determine 
whether the nucleotide sugar gradient was maintained. Duplicate 25/~1 sam- 
ples were centrifuged and the total amount of [3H] in the membrane pellets 
was determined as described above. To correct for [3H] incorporated into 
protein during the incubation, duplicate 25 ~1 samples were centrifuged,  the 
pellets solubilized in 25/~1 of 0.015 % sodium deoxycholate, and the protein 
precipitated with 5% cold TCA. The precipitate  was collected by centrifu- 
gation, washed twice with 100 #l of cold ethanol, and transferred to vials 
for scintillation counting.  The soluble UDP-[3H]-GIcNAc remaining in the 
membranes was determined by subtracting the radioactivity  incorporated 
into protein from the total radioactivity  of the pellets. 
The effect of the peptides on the sedimentation of Golgi membranes was 
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branes by incubation in a transport reaction mixture for one hour. Inhibitors 
were added and the mixtures incubated an additional 10 min at 37°C. Dupli- 
cate 25 ~1 samples were centrifuged and the radioactive protein in the pellet 
determined by TCA precipitation, as described above. 
Preparation of  Pertussis Toxin-treated  Membranes 
CHO lec 1 and pro-5 cells were incubated for three hours in media con- 
talning 0.1 btg/mi pertussis toxin along with parallel cultures of untreated 
cells. After this treatment, the lec 1 cells were infected with VSV following 
the standard protocol, and donor and acceptor membrane fractions were 
then prepared from homogenates of treated and untreated cells. The extent 
of ADP ribosylation of G~ subunits in viva was determined by in vitro 
ADP ribosylation of treated and untreated membranes with [32PI]-NAD 
and pertussis toxin (6). The relative content of [32p] in the samples was de- 
termined by densitometry after SDS-PAGE and autofluorography.  Approxi- 
mately 80% of G= was ADP ribosylated in viva in both the donor and ac- 
ceptor membrane  fractions.  The  amount of [3H]-GIcNAc  incorporated 
into VSV-g protein in assays containing 1 pg each of donor and acceptor 
membrane was 2,400 cpm for mock-treated membranes, and 2,500 cpm for 
pertussis toxin-treated membranes. A  second preparation of membranes 
gave qualitatively similar results. 
Electron Microscopy 
Freshly isolated Golgi-enriched membrane fractions were immobilized on 
3 mm  2 polylysine- and glutaraldehyde-treated coverslips, as previously de- 
scribed (53). The amount of membrane protein immobilized per coverslip 
was 0.08  +  0.02/zg, as determined with 35S-labeled membranes. The im- 
mobilized membranes were incubated in vitro with 8 pl of a standard trans- 
port reaction mixture (0.01/~g/ml membrane protein) for 10 rain. Since the 
effects of the inhibitors under study were strongly dependent on both the 
cytosol and membrane protein concentrations, titrations of the inhibitors in 
100/~1, standard transport reactions containing 0.01/.tg/mi  total membrane 
protein were used to determine the relevant concentration ranges for cyto- 
solic protein and inhibitors used in these studies, as stated in the legends. 
After in vitro incubation, the immobilized membranes were fixed, quick 
frozen, deep-etched, and replicas prepared for transmission electron mi- 
croscopy, as previously described (19, 53). 
Quantitative Analysis of  Electron Micrographs 
Micrographs of Golgi membranes were taken from two coverslips for each 
experimental  sample  (approximately  10  micrographs  per  coverslip). 
100-150 negatives from each experiment containing six to eight individual 
samples, were randomized for analysis. Negatives were projected at 2.6-fold 
magnification onto a  15  or 20 mm  2 grid using a  Bessler enlarger.  The 
negative number, the magnification, the number of coated buds and vesi- 
cles, the area encompassing the Golgi membranes relative to the grid, and 
abnormal morphological characteristics, such as the presence of long tu- 
bules, clusters of uncoated bud-like protrusions, irregular fragments of tu- 
bules and vesicles, were recorded. After all of the negatives for a given ex- 
periment were scored, the data were entered into a spreadsheet program, 
sorted by negative number, and then grouped by experimental sample for 
calculation of the average bud and vesicle densities and the fraction of com- 
plexes exhibiting abnormal morphology. 
Results 
Inhibition of Transport Is Specific  for Active Peptides 
The in vitro Golgi transport assay was used to biochemically 
characterize the inhibition of transport caused by MAS and 
ARFp13. As shown in Fig. 2 A, MAS is the more potent pep- 
tide inhibitor with an ICso of 0.75 pM. MAS 7, a variant of 
MAS that also stimulates GDP/GTP exchange on trimeric G 
proteins (22), is equally effective at inhibiting transport. In 
contrast, an inactive variant of MAS, MAS17 (22), is not in- 
hibitory, indicating that inhibition is  specific for peptides 
that activate trirneric G proteins. The concentrations of  MAS 
and MAS7 that inhibit t~ansport are similar to those that in- 
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Figure 2. MAS and ARF peptides exhibit the selectivity expected 
for specific inhibitors of in vitro Golgi transport. Standard in vitro 
Golgi transport assays were performed as described in Materials 
and Methods. (A) Incubations contained 0.3 and 0.15 mg/ml cyto- 
solic and membrane protein, respectively, and the indicated con- 
centration of MAS (B), MAS7 (t3), or MAS 17 (e). In the absence 
of peptide, the incorporation of [3H]-GIcNAc into VSV-g protein 
was 3,4000 cpm (n =  3). (B) Incubations contained 0.35 and 0.14 
mg/ml cytosolic and membrane protein, respectively, and the indi- 
cated concentration of ARFpl3 (m) or ARFp28 (e). In the absence 
of peptide, the incorporation of [3H]-GIcNAc into VSV-g protein 
was 8,300 cpm. The biochemical data shown in this and all other 
figures and tables are representative of two or more independent 
experiments. 
hibit release of vesicles from the TGN in vitro (29), but lower 
than those that induce binding of B-COP to isolated Golgi 
membranes and Golgi membranes in semi-intact cells (26). 
The NH~-terminal ARF peptide, ARFpl3, a potent inhibi- 
tor ofARF ADP-ribosylating activity (24), inhibits transport 
with  an  IC5o of 20-25  #M  (Fig.  2  B),  as  previously 
reported by others (24). ARFp28, a shorter peptide that has 
no effect on the ADP-ribosylating activity of ARE is not in- 
hibitory, indicating that inhibition of transport is correlated 
with ability to block other ARF-dependent functions. The 
inhibition of transport caused by both peptides thus meets 
these basic criteria for specificity. 
Inhibition Is Sensitive to Membrane and Cytosolic 
Protein Concentrations 
It has been shown that activation of reconstituted trimeric G 
proteins by MAS is dependent on the ratio of MAS to phos- 
pholipid (21), and not on the total concentration of MAS in 
solution. This suggests that it is the concentration of peptide 
in the membrane,  not the total concentration, that deter- 
mines  the  extent  of response  (21).  For  both  MAS  and 
ARFpl3, the effective  peptide concentration for inhibition of 
transport increases with increasing concentration of Golgi- 
enriched membranes in the assay (Table I A). This is consis- 
tent with a membrane-associated mode of action for both 
MAS and ARFpl3. 
The IC~o for both peptides also increased with increasing 
concentration of cystosol in the transport assay (Table I B). 
The ability of cytosol to abrogate ARFpl 3-induced inhibi- 
tion is not due to competition with cytosolic ARE It has pre- 
viously been shown that inhibition by ARFpl3 is indepen- 
dent of the ARF concentration in the assay (47).  We also 
found that the IC50 for MAS  and  ARFpl3  was  the  same 
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and Membrane Protein Concentrations 
MAS  ARFpI3 
IC~o (t~M) 
(.4) Membrane concentration 
0.11 mg/ml  1.7  32 
0.22 mg/ml  2.3  37 
0.44 mg/ml  3.0  41 
(B) Cytosol concentration 
0.14 mg/ml  0.6  10 
0.28 mg/ml  0.8  18 
0.56 mg/ml  1.2  28 
The concentration of MAS and ARFpl3 that produced half maximal inhibition 
of the  in vitro  Golgi transport  assay (IC50) were determined  from the best 
polynomial fit of titration curves,  such as those in Fig.  1. (.4) Each titration 
contained the indicated concentration of membrane protein  and 0.58  mg/ml 
cytosol. (B) Each titration contained the indicated concentration of cytosol and 
0.10  mg/ml membrane protein. 
when  assayed  with  either  normal  or  ARF-depleted  (46) 
cytosol (data not shown).  Four fractions of bovine brain 
cytosol that together contain all of the necessary soluble fac- 
tors for transport (11) were tested individually for their abil- 
ity to block the inhibition. All four fractions were equipotent 
in their ability to shift the IC5o of each peptide (data not 
shown), suggesting that there is no single component respon- 
sible for the blocking activity of cytosol. Preincubation of 
the peptides with cytosol at 37°C resulted in loss of their in- 
hibitory activity over a period of 5-15 min, suggesting that 
the peptides were being degraded or otherwise inactivated. 
This loss of inhibitory activity was not prevented by protease 
inhibitors such as phenymethylsulfonyl fluoride, leupeptin, 
peptstatin,  or  aprotinin,  but  was  significantly  slowed  by 
treating the cytosol with 1 mM NEM at 37°C for 15 min be- 
fore adding the peptide (data not shown). The blocking effect 
of cytosol thus appears to result from accelerated inactiva- 
tion of the peptides, and not competition between a specific 
cytosolic factor and the peptides. 
MAS and ARFpI3 Inhibit the Same Late Step in 
lntra-Golgi Transport 
The observation that MAS stimulates (26) and ARFpl3 in- 
hibits (24) 3-COP binding to Golgi membranes suggests that 
these peptides should block transport at different stages. To 
delineate the last step in transport that is sensitive to each 
peptide, the rates of  formation of  transport intermediates that 
are resistant to inhibition by these peptides was determined 
(2). In this analysis, inhibitor is added at various times after 
initiation of the transport incubation. The incubation is then 
continued to permit existing transport intermediates that are 
resistant to the inhibitor to complete the transport cycle. Fig. 
3 A show the rates of formation of previously characterized 
transport  intermediates.  The low  cytosol requiring  inter- 
mediate (LCRI; 51) is formed very early in the reaction, and 
the GTP~/S-resistant intermediate (GTP3,S; 33) forms some- 
what later. The 37°C NEM-resistant intermediate (NEM; 2) 
is formed only very late in the reaction, as indicated by the 
overall rate of VSV-g protein transport and glycosylation in 
the  absence  of inhibitors  (ice).  Under  these  Conditions, 
NEM inactivates not only NSF but other components as well 
(52; see below). 
Fig.  3  (B and  C)  shows that intermediates resistant to 
100- 
o  80. 
¢1 
~  60- 
E  •  ~  40- 
20- 
0 
100- 
~  80- 
60- 
E 
•  ~  40- 
'6  20-  N 
o! 
o 
Y  //  -.-o,,. 
=~,  ,  7"=I-; =  7 
~?"  -.-  = 
10 
!'  j 
//,/  ÷  .= 
20  30  40  50  60  0  10  20  30  40  50  60 
AT, minutes  AT, minutes 
Figure 3. Transport becomes resistant to inhibition by MAS and 
ARFpl3 only very late in the transport reaction. In vitro transport 
was initiated by transferring reaction mixtures to 37°C. At the indi- 
cated times (AT), inhibitors were added and the incubation con- 
tinued for a total of 60 min to permit inhibitor-resistant transport 
intermediates to complete the transport process. (A) The rate of 
formation of previously characterized transport intermediates: the 
LCRI (A) was detected by diluting the transport reaction fivefold 
with a reaction mixture lacking cytosol; the GTPTS resistant inter- 
mediate (*) was detected by adding 10 #M GTPqcS; and 1 mM 
NEM was added to detect the 37°C NEM-resistant intermediate 
(e). For comparison, the rate of VSV-g protein transport in the ab- 
sence of inhibitors was monitored by terminating the reaction on 
ice (B). The maximum incorporation of [3H]-GIcNAc  into VSV-g 
protein at 60 min for all samples was 4,600 cpm. (B-D) The rate 
of formation of the 37°C NEM-resistant intermediate (e) and the 
overall rate of VSV-g protein transport (B) is compared with the 
rates of formation of transport intermediates resistant to (B) 2.2 
#M MAS, (C) 56 #M ARFpl3, and (D) 50 #M SDS (o). The maxi- 
mum incorporation  of [3H]-GlcNAc into  VSV-g protein for all 
samples at 60 min was 4,500 (B), 19,500 (C), and 8,200 cpm (D). 
MAS and ARFp13, respectively, form only very late in the 
transport  reaction,  coincident  with  the  formation of the 
NEM-resistant intermediate. Thus, in contrast to the predic- 
tion, both peptides block the same step in transport, and this 
block occurs very late in the reaction, when transport is 
nearly complete. Moreover, inhibition of  the same late trans- 
port step is also observed with low concentrations of the an- 
ionic detergent, SDS (Fig. 3 D). Inhibition of this late trans- 
port  step  is  thus  not  specific  for  cationic  amphipathic 
peptides, as expected if inhibition was due to activation of 
a trimeric G protein. 
MAS and ARFpI3 Inhibit Glycosylation 
of VSV-g Protein 
It has been demonstrated that glycosylation  becomes the rate 
determining step in the measurement of VSV-g protein trans- 
port in this assay (20, 47). The late transport step inhibited 
by these peptides  might thus  correspond to  inhibition of 
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Figure 4.  MAS inhibits glycosylation of VSV-g protein  after its 
delivery to the acceptor compartment.  Membranes were incubated 
in a standard transport reaction lacking UDP-[aH]-GlcNAc for 45 
rain  to accumulate  VSV-g protein  in the acceptor compartment. 
The reaction mixture was split into three parts and incubated at 
37"C for an additional 15 rain with either no inhibitor (*), 2.2 #M 
MAS (o), or 1 mM NEM (B). After neutralization  of unreacted 
NEM with 2 mM D'FI', the membranes were re-isolated by cen- 
tfifugation and incubated in a glycosylation buffer containing UDP- 
pH]-GIcNAc for the indicated times (see Materials and Methods 
for details). The dashed line indicates the amount of incorporation 
observed in a control sample where UDP-I~H]-GlcNAc was added 
at the beginning of the transport  incubation. 
VSV-g protein glycosylation after it has been delivered to the 
acceptor  compartment.  To  test  this  possibility,  transport 
reactions were incubated in the absence of UDP-[3H]-GIc  - 
NAc for 45 min to accumulate VSV-g protein in the acceptor 
compartment. Inhibitory concentrations of the peptides were 
added and the incubation continued for an additional 15 min. 
The membranes were then re-isolated and incubated in gly- 
cosylation buffer containing  UDP-pH]-GIcNAc in the ab- 
sence of peptides (20), 
When the membranes are not exposed to peptides at the 
end of the transport incubation, the level of glycosylation ob- 
served in the second stage (Fig. 4, control) is equivalent to 
the  amount  of  glycosylation  measured  when  UDP-[3H]- 
GlcNAc is added at the beginning of the transport reaction 
(dashed line; 20). In contrast, when membranes are treated 
with either MAS or NEM after transport is complete, subse- 
quent glycosylation is inhibited.  Identical results were ob- 
tained withARFpl3 (data not shown). These data also dem- 
onstrate that the inhibition of glycosylation is irreversible, 
since the free peptides were removed prior to the glycosyla- 
tion incubation. Neither peptide was found to inhibit the ac- 
tivity of Gal transferase or GIcNAc transferase in soluble en- 
zyme assays, indicating that inhibition was not due to a direct 
inhibitory  effect of the  peptides  on  glycosyl transferases 
(data not shown). 
The Peptides Inhibit Uptake of Sugar Nucleotide 
Precursors by Golgi Membranes 
To further investigate the mechanism by which these pep- 
tides  inhibit  glycosylation,  VSV-infected  wild  type  Golgi 
were used to measure uptake of nucleotide sugars and the in- 
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Figure 5. Late  inhibition of transport correlates with generalized in- 
hibition of nucleotide sugar uptake and protein glycosylation. MAS 
(3.3 #M), ARFpl3 (43/zM),  NEM (1 raM), or SDS (50/~M) were 
added to standard transport reaction mixtures containing 0.3 mg/ml 
cytosolic  protein  and  0.15 mg/mi  of either  donor and  acceptor 
membranes  (transport)  or  transport  incompetent,  VSV-infected 
wild type membranes (all other measurements).  The effects of the 
inhibitors on glycosylation of endogenous VSV-g  protein, uptake of 
nucleotide sugars, membrane integrity as measured by retention of 
UDP-I~H]-GIcNAc, and  sedimentation  of [~H]-GlcNAc-labeled 
proteins  with  Golgi membranes  were measured  as described  in 
Materials and Methods. The values for each inhibitor are expressed 
as percent oftbe control (no inhibitor) and are the average of dupli- 
cate determinations.  The deviation of duplicates from the average 
in all samples was 7 % or less.  (,4) Reaction mixtures contained 
0.25/~Ci  UDP-[3H]-GIcNAc. Control  values were 4,500  +  500 
cpm (n = 8) for transport,  1,600 + 200 clam (n =  8) for glycosyla- 
tion, 2,500 + 400 clam (n =  8) for uptake, 6,400-16,700 cpm for 
integrity, and 7,100 +  500 cpm (n  =  2) for sedimentation.  (B) 
Reaction  mixtures  contained  0.25 /zCi UDP-[3H]-Gal.  Control 
values were 900  +  150 cpm (n =  8) for glycosylation and 3,500 
+  500 cpm (n =  8) for uptake. (C) Reaction mixtures contained 
0.25/zCi of CMP-[3H]-sialic acid.  Control values were 1,300 5: 
300 cpm (n  =  8) for glycosylation and 9,300  +  1,100 cpm (n  = 
8) for uptake. 
corporation of radiolabeled  sugars into VSV-g protein al- 
ready residing in the various Golgi biosynthetic compart- 
ments (47). The membranes were incubated under the same 
conditions  that  reconstitute  transport,  but  transport  was 
prevented by inactivation of endogenous NSF (5). Fig. 5 A 
shows that concentrations of MAS, ARFpl 3, NEM, and SDS 
that optimally inhibit transport have a  similarly inhibitory 
effect on the glycosylation of VSV-g protein and uptake of 
UDP-[3H]-GlcNAc, suggesting that inhibition of glycosyla- 
tion is due to the absence of luminal UDP-pH]-GIcNAc in 
the Golgi membranes. Fig. 5 (B and C) show that these in- 
hibitory effects on nucleotide sugar uptake and glycosylation 
are not restricted to compartments containing the GIcNAc/ 
UMP  translocase.  There  is  also  significant  inhibition  of 
uptake  and  glycosylation  when  UDP-[3H]-galactose  and 
CMP-pH]-sialic acid are used as substrates,  although the 
extent of inhibition is generally not as severe. 
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compounds directly inhibit the nucleotide-sugar transloca- 
tors, or if they permeabilize the membranes. To distinguish 
between these possibilities, the integrity of the membranes 
after incubation with the peptides, as assessed by their ability 
to  maintain a  performed gradient of UDP-pH]-GlcNAc, 
was determined. As shown in Fig. 5 A, ARFpl3 and SDS ap- 
pear to directly inhibit uptake,  since the integrity of the 
membranes is only partially compromised. In contrast, inhi- 
bition of uptake by MAS and NEM correlates with near 
complete loss of membrane integrity. This loss of integrity 
was not, however, due to a significant breakdown of Golgi 
structure per se. 90% or more of Golgi proteins pre-labeled 
with [3H]-GlcNAc during a 60-min incubation without in- 
hibitors still sedimented with the membranes after a second 
incubation that included the inhibitors (Fig. 5 A). It therefore 
seems likely that inhibition of nucleotide sugar uptake is due 
to a sub-lyric detergent-like effect of these peptides, and not 
to activation of a trimeric G protein. 
Inhibition of Transport Is Insensitive to Agents That 
Modify G Protein Activity 
The ICes for inhibition of the overall transport reaction by 
MAS and ARFpl3 are consistently lower than the IC~0's for 
inhibition of glycosylation  alone (Table II A). This increased 
sensitivity of the transport assay could be due to a specific 
effect of the peptides on GTP-binding proteins, which might 
be masked by the non-specific effects on protein glycosyla- 
tion occurring at slightly higher peptide concentrations. If 
this is true, then treatments that prevent the peptides from 
modulating GTP-binding protein activity would be expected 
to decrease the sensitivity of the transport assay to the pep- 
tides. Since these treatments would not affect the non-spe- 
cific  inhibition  of  glycosylatlon,  the  ICso for  transport 
should increase to the same level observed for inhibition of 
glycosylation alone.  To test this possibility, several treat- 
ments that have previously been shown to block the effects 
of MAS in other systems were examined. 
The fungal metabolite, brefeldin A (BFA) can prevent ei- 
ther MAS-induced (26) or GTPTS/ARF-induced binding of 
B-COP  to Golgi membranes (17). In addition, BFA over- 
comes the inhibition of in vitro Golgi transport caused by 
GTP-yS and ARF (38).  Table IIB shows that BFA is com- 
pletely  ineffective  at  increasing  the  ICso for  MAS  or 
ARFpl3 in the transport assay,  even though inhibition by 
GTPTS was blocked under the same conditions. The effects 
of MAS can also be abrogated by pre-treatlng the cells with 
pertussis toxin (26, 29), suggesting that the target of MAS 
is one of the pertussis toxin-sensitive trimeric G proteins, 
Gi or Go. As shown in Table II C, Golgi membranes pre- 
pared from pertussis toxin-treated cells are just as suscepti- 
ble as untreated membranes to inhibition of transport by 
these peptldes. Lastly, since GTP is required for activation 
of GTP-binding proteins, we tested whether the effect of the 
peptides on transport would be altered by including GTP in 
the assay.  Table II D  shows that 50 gM GTP was without 
effect on the ICs0 for transport. We conclude that inhibition 
of transport by these peptides is unrelated to specific effects 
on the function of GTP-binding proteins, and is most likely 
due to a general disruptive effect of the peptides on mem- 
brane function. 
Table II. Inhibition of In Vitro Transport by the Peptides 
Is Insensitive to Agents that Modulate GTP-binding 
Protein Activity 
MAS  ARFp  13 
IC5o (tiM) 
(A) Time of peptide addition 
(a)  low total protein 
before transport  0.8  18 
before glycosylation  1.9  27 
(b) high total protein 
before transport  2.0  35 
before glycoslyation  2.8  45 
(B) Addition  of BFA 
0/zM  2.2  36 
200/~M  2.0  34 
(C) Pertussis toxin treatment 
mock-treated membranes  1.3  29 
treated membranes  1.3  30 
(D)  Addition of GTP 
0/~M  1.4  27 
50/~M  1.3  27 
The IC50 was determined from titration curves as described in Table 1.  (A) 
Peptide was addded either prior to initiating the transport reaction, as in Figure 
1, or after transport was completed but before glycosylation, as in Figure 3. 
(a)  The cytosol and membrane protein concentrations were 0.29  and 0.12 
mg/ml, respectively. (b)  The cytosol and membrane protein concentrations 
were 0.56 and 0.22 mg/nd, respectively. (B) Each titration contained the indi- 
cated concentration of BFA with 0.58 m_glrni cytosol and 0.13 mg/ml mem- 
branes. Control samples demonstrated that BFA was effective  at preventing 
inhibition of transport by GTPTS under these conditions. (C) Donor and accep- 
tor membranes were prepared from pertussis toxin-treated cells, as described 
in Materials and Methods. Approximately 805[ of the reactive G subunits were 
ribosylated, and the specific transport activities of mock-treated and -untreated 
membranes were indentical  (see Materials and Methods for details). Assays 
contained 0.35 mg/ml cytosolic and 0.07 mg/ml membrane protein. (E) Assays 
contained the indicated concentrations of GTP with 0.30 mg/ml cytosol and 0.2 
mg/ml membrane protein. The variation in control IC5o values is due to the 
different cytosol and membrane protein concentrations in each experiment. 
The Peptides Have Complex Effects 
on Golgi Ultrastructure 
Our biochemical analysis demonstrates that the effects of 
MAS and ARFpl3 on in vitro transport are indistinguish- 
able. Nevertheless, previous studies have documented that 
these peptides have the exact opposite effects on binding of 
B-COP to Golgi membranes (24, 26). To further investigate 
this paradox, we used a new technique for obtaining high 
resolution, three-dimensional images of immobilized Golgi 
after in vitro incubation to examine the effect of the peptides 
on Golgi morphology (53).  For these experiments, the con- 
centrations of  cytosol and peptides were adjusted to compen- 
sate for the low concentration of immobilized membranes in 
the in vitro incubations (see Materials and Methods for de- 
tails). 
The morphology of immobilized Golgi membranes in- 
cubated  with  the  non-inhibitory  peptides,  MAS17  and 
ARFp28, was indistinguishable from that of control mem- 
branes (Fig. 6 A) incubated without peptides, and the density 
of coated buds and vesicles was also the same (Fig. 7 A). In 
contrast, Golgi cisternae with typical morphology decreased 
in abundance or were altogether absent after a 10-min incu- 
bation at 37°C with either MAS or ARFpl3 (Fig. 7 A). In- 
stead, cisternae with clusters of uncoated bud-like structures 
at the periphery (Fig. 6 C), and regions of irregular vesicles, 
tubules, and membrane discs suggestive of shattered cister- 
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and peptides, cisterna-like structures with long tubular loops 
were also observed.  In some cases,  the tubular loops ex- 
hibited patches of a dense, punctate coat and coated buds 
(Fig. 6 E). In other instances the tubules were smooth sur- 
faced (Fig. 6 F). All of these aberrant forms were observed 
with both peptides, with the exception that tubular cisternae 
with a  dense punctate coating (Fig.  6 E) were more fre- 
quently observed with MAS  than ARFpl3.  These effects 
were only occasionally observed after treatment with SDS. 
However,  SDS-treated membranes had a  lower density of 
coated buds (Fig. 7 A) and frequently appeared swollen and 
distorted, as though they were in the process of pulling away 
from the substrate (cisternae in top right corner, Fig. 6 B). 
Similarly distended cisternae  were  also  occasionally ob- 
served after incubation with low concentrations of peptides. 
With the possible exception of the shattering of membranes, 
the disruption of morphology induced by the peptides is not 
a direct consequence of immobilization of the membranes. 
The same abnormalities were observed when membranes 
were incubated with MAS in suspension, and then attached 
to the coverslips (data not shown). 
Quantitative analysis revealed a coordinate decrease in the 
density of coated buds and vesicles and in the fraction of 
cisternae exhibiting normal morphology with increasing con- 
centration of MAS or ARFp13 (Fig. 7, B and C). This de- 
crease paralleled the inhibition of in vitro Golgi transport 
measured in reactions containing the same concentrations of 
membrane and cytosolic protein. In addition, the density of 
Golgi and other contaminating membranes on the coverslips 
also decreased. Approximately 9-14 profiles of Golgi stacks 
or individual cisternae were observed per 55  ×  55/~m grid 
space in control incubations. In samples incubated with the 
highest concentrations of peptides, this value fell to one or 
less profile per grid space with a commensurate decrease in 
non-Golgi membranes, suggesting that membranes had de- 
tached during the incubation. These results suggest that both 
inhibition of in vitro Golgi transport and inhibition of coated 
vesicle formation are due to membrane damage induced by 
the peptides, and not to a specific effect on Golgi vesicle dy- 
namics, in agreement with the biochemical evidence. 
Since these Golgi membrane preparations contain con- 
taminating plasma membrane fragments, it is possible that 
the membrane disruption observed could be due to activation 
of plasma membrane-associated trimeric G  proteins with 
subsequent activation of soluble phospholipases. We there- 
fore determined whether inactivation of Gi and Go, the pre- 
sumed targets of MAS, by pertussis toxin-catalyzed ADP- 
ribosylation prevented the morphological changes induced 
by incubation with MAS (Table HI A). Pertussis toxin treat- 
ment had no effect on the transport activity of Golgi mem- 
branes  (see Materials and Methods for details) or on the 
IC~o for inhibition of transport by either MAS or ARFpl 3 
(Table II). This treatment did, however,  result in a  1.4-fold 
increase in Golgi-coated bud and vesicle density after a  10 
rain in vitro transport incubation (Table HI A; also compare 
Figs. 6 A and 8 A). Although small, this increase was statisti- 
cally significant when compared with mock-treated mem- 
branes in the same experiment (P < 0.05), and with all of the 
control membranes analyzed in this study (four prepara- 
tions, P  <  0.01). The ability of MAS to disrupt the mor- 
phology ofpertussis toxin-treated membranes was similar to 
that observed with mock-treated membrane,  s. Pertussis toxin- 
treated cisternae with disrupted morphology exhibited the 
same gross abnormalities as mock-treated membranes, but 
had a significantly higher density of coated buds (Fig. 8 B, 
Table HI A). The ability of MAS to alter the morphology of 
pertussis toxin-treated membranes confirms our conclusion 
that  these  morphological  changes  are  the  result  of the 
detergent-like properties of MAS. 
In the experiments described above, the membranes were 
incubated in vitro for only 10 min. Since a significant popu- 
lation of cisternae with apparently normal morphology was 
observed after short incubations at peptide concentrations at 
or below the ICs0 (Fig. 7, B and C), it was of interest to 
know whether these  populations would maintain normal 
morphological characteristics during the longer incubations 
required to measure transport in the in vitro assay. We have 
previously  shown  that  a  10-min  in  vitro  incubation  is 
sufficient  to establish a steady state of vesicle production and 
consumption on immobilized Golgi (53).  After prolonged 
incubation,  the coated bud  and vesicle density increases 
1.3-1.5-fold (control,  Table III B), but the size of cisternae 
decreases commensurately (53), suggesting that vesicles are 
continuously released but do not efficiently transfer in this 
system. When immobilized membranes were incubated with 
either MAS or ARFpl3, coated bud and vesicle densities in- 
creased 2.5-3-fold between 10 and 45 min of incubation, to 
nearly twice the level observed with untreated membranes 
(Table 1II B).  This increase occurred without a  commen- 
surate decrease in the size of cisternae, and did not result in 
the accumulation of fully formed vesicles that failed to de- 
tach. Of the coated structures that could be clearly identified 
(at least 60% of the total), '~85% were coated buds in all 
three 45 min samples. There was also a notable decrease in 
the fraction of  cisternae exhibiting abnormal morphology af- 
ter 45 min of incubation, suggesting that these cisternae may 
represent a subpopulation of the original membranes. These 
data demonstrate that, after incubation with MAS or ARF- 
p13, even cisternae with apparently normal morphology ex- 
hibit abnormal coated bud and vesicle dynamics. 
Discussion 
We have biochemically and morphologically characterized 
the mechanism of action of two amphipathic peptides, MAS 
and ARFpl3,  on in vitro Golgi transport.  These peptides 
were previously thought to specifically interfere with the 
function of two distinct GTP-binding proteins that regulate 
Golgi-coated vesicle dynamics, and have been shown to have 
opposing effects on Golgi vesicle coat protein binding (24, 
26). Our detailed analysis reveals that both peptides inhibit 
in vitro Golgi transport by inducing membrane damage, and 
not by specifically interfering in GTP-binding protein func- 
tion. We further demonstrate that, at concentrations below 
those that completely disrupt cisternal architecture and in- 
hibit in vitro transport, both MAS and ARFpl3 have subtle 
effects on Golgi-coated bud and vesicle dynamics. While the 
damaging effects of  the peptides are not reversed by pertussis 
toxin-treatment of the membranes, this treatment alone also 
has a subtle effect on coated vesicle dynamics. These results 
raise important issues concerning both the interpretation of 
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Figure 7. Disruption of cisternal structure and reduced coated bud 
and vesicle density is specific for MAS and ARFpl3, and correlates 
with inhibition of transport.  Immobilized Golgi membranes were 
incubated for 10 min in vitro, and processed for electron micros- 
copy as described in Materials and Methods. Randomized negatives 
were scored for the density of coated buds and vesicles (stippled 
bars),  and  for abnormal  morphological  characteristics  such  as 
swelling, clusters of uncoated buds, long tubules and shattering, as 
shown in Fig. 5 (C-F). Data are reported as the fraction of cisternae 
previous studies that used these peptides and the use of pep- 
tides in general as specific reagents for analyzing protein 
function in complex in vitro systems. 
The Primary Mechanism of Inhibition 
of In Vitro Golgi Transport 
Our biochemical and morphological data strongly support 
the conclusion that inhibition of transport and glycosylation 
by these peptides is due to disruption of the membrane. Both 
peptides  form arnphipathic  helices  that can partition  into 
membranes (21,  24) and other have reported that high con- 
centrations of MAS can damage membranes (21, 29). To our 
knowledge,  however, this is the first report to specifically 
document these effects in biological membranes, and to dem- 
onstrate generalized membrane disfunction at peptide con- 
centrations below those necessary to completely permeabi- 
lize membranes. 
Sublytic concentrations of ARFpl3 and SDS exhibit dis- 
tinct  concentration-dependent  effects on  membrane func- 
tion.  Transport  was  most  sensitive  to  inhibition,  while 
slightly  higher  concentrations  inhibited  facilitated  mem- 
brane transport, and even higher concentrations were needed 
to completely permeabilize the membranes (Fig. 5 A, Table 
II). A similar effect was observed with MAS (Table II), al- 
though inhibition of facilitated transport and permeabiliza- 
tion of the membranes could not be resolved. Surprisingly, 
the alkylating agent,  NEM,  completely permeabilized the 
membranes after a  short incubation at 37°C.  This effect is 
specific for the oxidized form of NEM, since reduced NEM 
does not inhibit transport (2).  Although the mechanism of 
permeabilization is unclear, this finding raises the possibility 
that inhibition of various membrane functions by NEM could 
be due to an effect on membrane lipids rather than on pro- 
teins, as commonly assumed. 
The effects of the peptides on membrane function are par- 
alleled by an increase in the fraction of cisternae exhibiting 
exhibiting normal morphology (open bars). (A) Immobilized mem- 
branes were incubated for 10 minutes without inhibitors (control) 
or with  1.8/~M MAS, 2.0/~M MAS17, 42/~M ARFpl3,  45 /~M 
ARFp28, or 50 t~M SDS in a transport mixture containing 2 mg/ml 
cytosol. The IC5o for inhibition of in vitro transport under similar 
conditions  was approximately  1.0 ~tM for MAS and 20/~M  for 
ARFpl3.  (B and C) Membranes were incubated for 10 rain with 
a transport reaction mixture containing 1 mg/ml cytosol and inhibi- 
tots  as  indicated.  ATP was  omitted  from one  control  reaction 
(-A/P) to determine the nominal levels of normal cisternae and 
bud density under conditions that do not support budding. In vitro 
transport (black bars) was measured in 100/~1 reactions containing 
0.01 mg/ml membrane protein and the same cytosol at 1 mg/ml. The 
results are expressed as percent of transport relative to the control 
incubation without peptide (900 +  100 cpm, n = 4). The increase 
in bud and vesicle density on membranes incubated with 5.3 I~M 
ARFp13 is statistically  significant (Wilcoxon rank sum test, P < 
0.05). 
Figure 6. Inhibitory concentrations of MAS and ARFpl 3 drastically alter Golgi cisternal architecture. Golgi membranes were immobilized 
on coverslips, incubated with in vitro transport reaction mixtures for 10 min at 37°C, and replicas of the quick frozen, deep-etched mem- 
branes prepared for electron microscopy, as described in Materials and Methods. Transport incubations included: (A) no inhibitors;  (B) 
50 #M SDS; (C) 0.44/~M MAS; (D) 10.6 #M ARFpl3; (E) 1.8 ~M MAS; and (F) 42/~M ARFpI3. The cytosol concentration was 1 rng/ml 
in A-D and 2 mg/ml in E and E  Insets were magnified 2.5-fold to reveal the ultrastructure  of (A) the punctate coat on Golgi buds, (C) 
lack of a punctate coat on buds, and (D) punctate coat on the surface of a tubule. Bars, 0.3 t~m. 
Weidman and Winter Effects of Mastoparan and ARF13 on Golgi Transport  1823 Table III.  Coated Bud and Vesicle Dynamics Are Modified by MAS,  ARFpl3, and Pertussis  Toxin 
Treatment of Membranes 
Buds and vesicles  Buds and vesicles 
Percent normal  Percent normal 
Incubation conditions  /~m  2 +  S.E.  (n)  complexes  t~m  2 +  S.E.  (n)  complexes 
(.4)  Comparison of untreated and pertussis toxin-treated membranes 
Mock treated  Pertussis toxin treated 
control  9.7  5:0.3  (22)  82  13.5  5:0.3  (20)  80 
0.44/~M  MAS  11.7  +  0.9  (20)  50  7.2  +  0.3  (21)  43 
0.88/~M  MAS  2.5  5:0.5  (12)  0  7.6  5:0.8  (14)  14 
(B) Comparison of short and long incubations 
10-min incubation  45-min incubation 
control  7.7  +  1.0 (24)  96  10.1  +  1.7 (18)  100 
0.44 #M MAS  7.6  +  0.9 (19)  74  18.3 5:3.0 (17)  89 
10.6 #M ARFpl3  5.5  5:0.8 (9)  50  18.8 5:2.2 (17)  94 
Sample preparation and analysis were as described for Fig. 7. (A) Membranes prepared from either mock or pertussis toxin-treated cells, as shown in Table II 
and described in Materials and Methods, were incubated with 1 mg/ml cytosol and the indicated concentrations of MAS for 10 min. The IC~ for inhibition of 
transport under similar conditions was 0.4/~M MAS. The difference in bud and vesicle density between mock and pertussis toxin-treated control membranes is 
statistically  significant (Wilcoxon rank sum test, P  <  0.05). The majority of pertussis toxin-treated Goigi membranes identified  aRer incubation with 0.88 pM 
MAS were budding cister~ fragments that were, on the average, half the size of normal cisternae. (B) Membranes were incubated in a transport reaction mixture 
with 2 mg/ml cytosol, as described in Fig. 7 A. Half of the reactions were terminated after 10 rain and the remainder incubated for 45 rain. The elevated bud 
and vesicle densities observed after 45 rain of incubation with the peptides are statistically  significant (Wilcoxon rank sum test, P <  0.02 for MAS and P <  0.01 
for ARFpI3). 
morphological changes such as distortion of cisternal shape, 
elaboration of  bud-like protrusions or long tubules, and frag- 
mentation of membranes (Fig. 6).  A  similar tubularization 
of cisternae is observed after membranes are incubated with 
ATP in the absence of cytosol (53). We have suggested that 
these long tubules form on cisternae by rearrangement of the 
peripheral tubular networks in response to the loss of a sta- 
bilizing protein coat that is distinct from vesicle coats (53). 
It  is  therefore  of interest  that  peptide-induced  disruption 
of the  membrane also  resulted  in  tubular  rearrangements 
(Fig.  6,  E  and F),  even though  some tubules  exhibited  a 
punctate  surface coating  similar to that  found on vesicles 
(Fig. 6 E).  It is also of interest that the peptides caused an 
increase in the fraction of cisternae with abnormal morphol- 
ogy as their concentrations were increased, rather than caus- 
ing a gradation of effects on the entire population. Since par- 
tition coefficients are sensitive to lipid composition, and the 
lipid composition, especially the cholesterol content, varies 
across the Golgi stack (8), it is possible that cisternae on one 
side of the stack are more resistant to the damaging effects 
of the peptides. This is consistent with the observation that 
uptake of UDP-gal and CMP-sialic acid, presumably in the 
Figure 8. Membranes from pertussis toxin-treated  cells exhibit higher densities of coated vesicles but are not resistant to MAS-induced 
disruption of morphology. Membranes prepared from pertussis toxin-treated cells, as described in Materials and Methods, were incubated 
in vitro for 10 rain, and then prepared for electron microscopy as described  in Fig. 5. (A) No inhibitor;  (B) 0.44 pM MAS. Insets are 
magnified 2.5-fold to reveal the punctate coat on the buds.  Bars, 0.3 #m. 
The Journal of Cell Biology, Volume 127,  1994  1824 trans-most cisternae,  is less sensitive to inhibition by the 
peptides (Fig. 5, B and C). 
The fragmentation of membranes induced by the peptides 
(Fig. 6 D) seems to contradict the finding that membranes 
incubated with the peptides in suspension are readily sedi- 
mented (Fig. 5 A). Since the immobilized membranes are 
covalenfly attached to the coverslips,  this shattering may 
occur  when the  membranes are  unable  to  accommodate 
membrane expansion induced by intercalation of the pep- 
tides. The sedimentation velocity of  membranes treated with 
MAS is slightly greater than that of untreated membranes 
(Weidman, P., unpublished results), suggesting that the pep- 
tides do induce membrane swelling. Lastly, although the bio- 
chemical effects of SDS closely paralleled those of the pep- 
tides, its effects on morphology were minimal (Fig. 6 B). 
This may reflect differences between the shape or volume oc- 
cupied by SDS and the peptides in the lipid bilayer, and/or 
the ability of these compounds to transfer to the inner leaflet 
of the bilayer,  as  suggested by Sheetz  and Singer in  the 
bilayer couple hypothesis (42). 
ARFpl3 Is Not a Specific Inhibitor of  ARF Activity 
Our data clearly show that inhibition of vesicle formation by 
ARFpl 3 is due to disruption of membrane structure, and not 
to competition with ARF as originally proposed (24).  This 
difference in interpretation is not due to any subtle difference 
between our system and that of Kahn et al., since they also 
found that Golgi cisternae were rarely seen after incubation 
with ARFpl3 (24). Such a non-specific mechanism of inhibi- 
tion explains  the lack of competition between  ARF  and 
ARFpl3, and the inhibition of in vitro Golgi transport by 
ARFpl3, even though ARF is not required for transport (47). 
This same mechanism may underlie the inhibition of trans- 
port observed in other in vitro systems (3,  28,  34),  since 
similar concentrations of ARFpl3 were required, and com- 
petition between ARF and the ARF peptides for inhibition 
was not demonstrated. 
Limitations of  Mastoparan as a Tool 
for Analyzing Trimeric G Protein Function 
in Biological Systems 
Several studies have provided evidence that MAS increases 
Golgi coat protein binding and alters vesicle dynamics by 
modulating trimeric  G  protein  activity. In permeabilized 
cells, 10 #M MAS stimulates B-COP binding to Golgi mem- 
branes, and this effect is diminished either by pertussis toxin- 
treatment or by brefeldin A (26).  In addition, 25 #M MAS 
caused a 10-fold increase in the amount of B-COP bound to 
isolated Golgi membranes (26). p200 is BFA-sensitive pro- 
tein localized on trans-Golgi vesicles that accumulate after 
treatment with GTP~S or AIF (36).  Its binding to rat liver 
Golgi membranes in vitro is stimulated more than sevenfold 
by 100 #M MAS, and this stimulation is also diminished by 
pertussis toxin treatment (9). Despite the implication that ac- 
tivation of trimeric G proteins stimulates Golgi vesicle for- 
mation, inhibition rather than stimulation of transport is ob- 
served in vivo (45).  An alternative perspective has come 
from functional studies of  vesicle release from the TGN (29). 
At much lower concentrations (1 #M), MAS7 partially sup- 
presses the release of  both constitutive and regulated vesicles 
from the TGN of PC12 cells in vitro. Pertussis toxin-cata- 
lyzed ADP ribosylation of G~jo subunits stimulates vesicle 
release almost twofold and renders it insensitive to MAS. 
Vesicle release is also enhanced when G~s subunits are ac- 
tivated by cholera toxin-catalyzed ADP ribosylation. It has 
been  proposed  that  these  paradoxical  findings could  be 
reconciled if coated bud production is stimulated by activa- 
tion of G~ and fission of coated buds to produce coated 
vesicles is suppressed by activation of G~uo (32).  One of 
our objectives was to directly test this hypothesis using a 
combination of functional assays and high resolution ultra- 
structural analyses. 
It is clear from our functional analysis that the ability of 
MAS to inhibit in vitro Golgi transport is independent ofper- 
tussis toxin-sensitive pathways. In retrospect, this is not sur- 
prising, since we have recently demonstrated that transport 
in this system is independent of Golgi-coated vesicles (47). 
The effects of MAS reported in the studies described above 
are partly (9, 26) or fully (29)  reversed by pertussis toxin 
treatment, and similar effects are obtained with A1F4, sug- 
gesting that increased coat protein binding and changes in 
vesicle dynamics are associated with activation of trimeric 
G proteins. Nevertheless, our ultrastructural analysis sug- 
gests that MAS has the potential to introduce artifacts that 
complicate the elucidation of the mechanisms involved.  For 
example, incubation of  membranes with high concentrations 
of MAS and cytosol resulted in the elaboration of cisternal 
tubules that were encrusted with punctate material resem- 
bling the coats found on Golgi vesicles (Fig. 6 E). Assuming 
this punctate coat corresponds to vesicle coat proteins, this 
would represent a  substantial increase in the level of coat 
protein binding to Golgi membranes. Since this effect was 
seldom observed with ARFpl3, this accumulation might be 
the consequence of trimeric G protein activation. Alterna- 
tively, it has recently been shown that coatomers will bind 
to the di-lysine retention motif of ER membrane proteins 
(14). A high density of lysine residues exposed on the cyto- 
plasmic surface of Golgi, as would occur when MAS parti- 
tions into membranes, might thus serve as novel binding 
sites for coatomers. This possibility is of particular concern 
given that the massive increase in coat protein binding ob- 
served in in vitro binding assays occurred at extremely high 
levels of MAS, and was only partially inhibited by pertussis 
toxin treatment (9, 26). 
The accumulation of coated buds that occurred on a subset 
of cisternae after prolonged incubation of membranes with 
MAS (Table III B) provides an example of the difficulty in 
interpreting  more  subtle  effects  of MAS.  This  increase 
seemed to arise by a decrease in the rate of vesicle formation 
from buds, as opposed to a stimulation of budding, since it 
was not apparent early in the incubation, and the majority 
of coated structures that accumulated were buds, not vesi- 
cles.  Although the increase was  relatively small (1.8-1.9- 
fold), it is consistent with the modest effect of MAS on re- 
lease of vesicles from the TGN (•30%  inhibition, 29), but 
not with the substantial increase in coat protein binding ob- 
served in other studies. If this increase is due to activation 
of trimeric G proteins, these findings would support the pro- 
posed model for dual regulation of Golgi vesicle dynamics 
described above. However, it is also possible that slowing of 
vesicle fission is a general effect of low concentrations of 
membrane perturbants, since ARFpl3 also induced a similar 
increase in bud and vesicle density. 
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proteins in Golgi vesicle dynamics is the 1.4-fold increase in 
the density of  Golgi-coated buds and vesicles seen on pertus- 
sis toxin-treated membrane after a short transport incuba- 
tion (Table IIIA). This increase, although small, was sig- 
nificant when compared to all of the control membranes 
examined in this study, and was seen even on cisternal frag- 
ments produced during incubations with MAS. This increase 
might be due to a stimulation of coated bud formation, since 
it was apparent very early in the incubation, and its magni- 
tude is similar to the stimulation of TGN vesicle release ob- 
served after pertussis toxin treatment (approximately a 1.6- 
1.7-fold increase; 29). 
The subtle effects of MAS and pertussis toxin treatment on 
Golgi vesicle dynamics are thus consistent with the effects 
of these same treatments on vesicle release from the TGN 
(29), yet are inconclusive with regard to the mechanisms in- 
volved.  The pronounced membrane perturbing  effects  of 
these peptides suggest that alternative methods of approach 
will be needed to unravel the complexity of trimeric G pro- 
tein involvement in membrane transport. 
Implications  for Studies Using These 
and Other Peptide Reagents 
These studies demonstrate that the criteria for peptide spec- 
ificity accepted in the past are inadequate to rule out non- 
specific effects in such complex in vitro systems. In particu- 
lar, using peptides that have been shown to be inactive with 
purified proteins as indicators of specificity can be quite mis- 
leading, as demonstrated by the data in Fig. 2. Comparing 
the behavior of peptides with similar tendency to form am- 
phipathic helices in the presence of lipid is also not suffi- 
cient, since the propensity of ARFpl 3 and the non-inhibitory 
peptide, MAS17, to form ot helices in the presence of lipids 
is nearly identical (22,  24), yet MAS17 had no effect on in 
vitro transport at concentrations up to 50/~M (Weidman, P., 
unpublished observation). Lack of membrane permeabiliza- 
tion over the effective concentration range would also appear 
to be insufficient, since ARFpl3 did not significantly per- 
meabilize membranes at the concentrations needed to effect 
inhibition of  transport (Fig. 5 A). Moreover, our data suggest 
that the partition coefficient of peptides may vary with the 
lipid composition of the membrane,  such that acceptable 
concentrations for one intracellular membrane could be dis- 
ruptive for another. A further complication is the apparent 
inactivation of peptides by cytosol, which makes it difficult 
to know the actual peptide concentration, and gives the er- 
roneous impression that there is  specific competition be- 
tween the peptide and a cytosolic factor. 
These considerations and the observation that not all pep- 
tides with an affinity for membranes form amphipathic cx 
helices (25), raise the legitimate concern that more stringent 
controls are needed when any peptide reagent is used in such 
biological systems. One obvious criteria is that inhibition by 
a peptide should be preventable or reversible.  For example, 
inhibition should he overcome by competition with the pro- 
tein from which the peptide was derived, or by adding excess 
target protein. Alternatively, inhibition should be reversed 
upon removal of the peptide. Secondly, the peptide should 
not affect facilitated membrane transport in the membrane 
of interest, even at concentrations twofold higher than the 
effective range for inhibition of the process  under  study. 
Thirdly, morphological changed such as organeUe swelling, 
distortion,  fragmentation, or a  decrease in abundance of 
membranes with recognizable morphology should be viewed 
with suspicion.  Lastly, there may be independent criteria 
that can be applied. For example, it is clear that BFA and per- 
tussis toxin treatment had no effect on the inhibition of trans- 
port by MAS or ARFpl 3. 
In summary, we do not believe that our findings negate the 
utility of peptides as specific reagents for probing protein 
function, but they do emphasize the need for a stricter ap- 
proach in assessing the specificity of peptide action in bio- 
logical systems, especially when membrane-dependent pro- 
cesses are involved. 
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